Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis by Bertsias, GK et al.
Joint European League Against Rheumatism and
European Renal Association–European Dialysis and
Transplant Association (EULAR/ERA-EDTA)
recommendations for the management of adult and
paediatric lupus nephritis
George K Bertsias,1 Maria Tektonidou,2 Zahir Amoura,3 Martin Aringer,4
Ingeborg Bajema,5 Jo H M Berden,6 John Boletis,7 Ricard Cervera,8 Thomas Dörner,9
Andrea Doria,10 Franco Ferrario,11 Jürgen Floege,12 Frederic A Houssiau,13
John P A Ioannidis,14 David A Isenberg,15 Cees G M Kallenberg,16 Liz Lightstone,17
Stephen D Marks,18 Alberto Martini,19 Gabriela Moroni,20 Irmgard Neumann,21
Manuel Praga,22 Matthias Schneider,23 Argyre Starra,24 Vladimir Tesar,25
Carlos Vasconcelos,26 Ronald F van Vollenhoven,27 Helena Zakharova,28
Marion Haubitz,29 Caroline Gordon,30 David Jayne,31 Dimitrios T Boumpas1
▸ Additional data are
published online only. To view
these ﬁles please visit the
journal online (http://ard.bmj.
com)
For numbered afﬁliations see
end of article.
Correspondence to
Dr Dimitrios T Boumpas,
Department of Rheumatology,
Clinical Immunology, and
Allergy, University of Crete,
Faculty of Medicine, Iraklio,
Greece;
boumpasd@med.uoc.gr
Received 27 March 2012
Accepted 3 July 2012
Published Online First
31 July 2012
ABSTRACT
Objectives To develop recommendations for
the management of adult and paediatric lupus nephritis
(LN).
Methods The available evidence was systematically
reviewed using the PubMed database. A modiﬁed Delphi
method was used to compile questions, elicit expert
opinions and reach consensus.
Results Immunosuppressive treatment should be
guided by renal biopsy, and aiming for complete renal
response (proteinuria <0.5 g/24 h with normal or near-
normal renal function). Hydroxychloroquine is
recommended for all patients with LN. Because of a
more favourable efﬁcacy/toxicity ratio, as initial treatment
for patients with class III–IVA or A/C (±V) LN according
to the International Society of Nephrology/Renal
Pathology Society 2003 classiﬁcation, mycophenolic
acid (MPA) or low-dose intravenous cyclophosphamide
(CY) in combination with glucocorticoids is
recommended. In patients with adverse clinical or
histological features, CY can be prescribed at higher
doses, while azathioprine is an alternative for milder
cases. For pure class V LN with nephrotic-range
proteinuria, MPA in combination with oral glucocorticoids
is recommended as initial treatment. In patients
improving after initial treatment, subsequent
immunosuppression with MPA or azathioprine is
recommended for at least 3 years; in such cases,
initial treatment with MPA should be followed by MPA.
For MPA or CY failures, switching to the other agent, or
to rituximab, is the suggested course of action. In
anticipation of pregnancy, patients should be
switched to appropriate medications without reducing
the intensity of treatment. There is no evidence to
suggest that management of LN should differ in
children versus adults.
Conclusions Recommendations for the management of
LN were developed using an evidence-based approach
followed by expert consensus.
INTRODUCTION
Approximately 50% of patients with systemic
lupus erythematosus (SLE) will develop lupus
nephritis (LN), which increases the risks for renal
failure, cardiovascular disease and death. In 2008,
we published the ﬁrst European League Against
Rheumatism (EULAR) recommendations on the
management of SLE.1 Since then, several controlled
trials have been published upon which updated
recommendations can be based. The realisation
that in the care of patients with LN internists/
rheumatologists and nephrologists are involved,
prompted us to develop recommendations for LN
under the joint auspices of the EULAR and the
European Renal Association–European Dialysis and
Transplant Association (ERA-EDTA), with experts
from both disciplines. The panel was enriched
with renal pathologists and paediatricians with
expertise on LN.
METHODS
We followed the EULAR standardised operating
procedures2 and the Appraisal of Guidelines
Research and Evaluation instrument. We selected a
list of questions by a modiﬁed Delphi method
further edited for literature search, followed by a
systematic search of the PubMed database
(web-only appendix tables 1 and 2); all English lan-
guage publications up to December 2011 were con-
sidered. We further reﬁned retrieved items based on
abstract and/or full-text content, and the number
of patients (requiring n≥30 for diagnosis, monitor-
ing, prognosis; n≥ 10 for treatment). A detailed
presentation of the literature review is provided in
web-only appendix table 3. Evidence was cate-
gorised based on the design and validity of available
studies and the strength of the statements was
graded. After discussions, the committee arrived at
28 ﬁnal statements rated individually by each
member (tables 1 and 2).
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Table 1 Recommendations for the management of patients with systemic lupus erythematosus (SLE) with renal involvement
Statement
Mean
(SD)
Median
(IQR)*
1. Indications for first renal biopsy in SLE
Any sign of renal involvement—in particular, urinary findings such as reproducible proteinuria ≥0.5 g/24 h especially with glomerular haematuria
and/or cellular casts—should be an indication for renal biopsy. Renal biopsy is indispensable since in most cases, clinical, serological or laboratory
tests cannot accurately predict renal biopsy findings.
9.7 (0.5) 10 (1)
2. Pathological assessment of kidney biopsy
The use of the International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 classification system is recommended with
assessment of active and chronic glomerular and tubulointerstitial changes, and of vascular lesions associated with anti-phospholipid antibodies/
syndrome
9.6 (0.7) 10 (1)
3. Indications and goals of immunosuppressive treatment in lupus nephritis (LN)
3.1. Initiation of immunosuppressive treatment should be guided by a diagnostic renal biopsy. Immunosuppressive agents are recommended in class IIIA
or IIIA/C (±V) and IVA or IVA/C (±V) nephritis, and also in pure class V nephritis if proteinuria exceeds 1 g/24 h despite the optimal use of
renin-angiotensin-aldosterone system blockers
9.4 (0.7) 10 (1)
3.2. The ultimate goals of treatment in LN are long-term preservation of renal function, prevention of disease flares, avoidance of
treatment-related harms, and improved quality of life and survival. Treatment should aim for complete renal response with UPCR <50 mg/mol and
normal or near-normal (within 10% of normal GFR if previously abnormal) renal function. Partial renal response, defined as ≥50% reduction in
proteinuria to subnephrotic levels and normal or near-normal renal function, should be achieved preferably by 6 months but no later than 12 months
following initiation of treatment
9.6 (0.8) 10 (1)
4. Treatment of adult LN
Initial treatment
4.1. For patients with class IIIA or IIIA/C (±V) and class IVA or IVA/C (±V) LN, mycophenolic acid (MPA) (mycophenolate mofetil (MMF) target
dose: 3 g/day for 6 months, or MPA sodium at equivalent dose) or low-dose intravenous cyclophosphamide (CY) (total dose 3 g over 3 months) in
combination with glucocorticoids, are recommended as initial treatment as they have the best efficacy/toxicity ratio
9.3 (0.8) 9 (1)
4.2. In patients with adverse prognostic factors (acute deterioration in renal function, substantial cellular crescents and/or fibrinoid necrosis),
similar regimens may be used but CY can also be prescribed monthly at higher doses (0.75–1 g/m2) for 6 months or orally (2–2.5 mg/kg/day) for
3 months
8.8 (1.3) 9 (2)
4.3. To increase efficacy and reduce cumulative glucocorticoid doses, treatment regimens should be combined initially with three consecutive
pulses of intravenous methylprednisolone 500–750 mg, followed by oral prednisone 0.5 mg/kg/day for 4 weeks, reducing to ≤10 mg/day by
4–6 months
9.0 (1.1) 9 (2)
4.4. In pure class V nephritis with nephrotic-range proteinuria, MPA (MMF target dose 3 g/day for 6 months) in combination with oral
prednisone (0.5 mg/kg/day) may be used as initial treatment based on better efficacy/toxicity ratio. CY or calcineurin inhibitors (ciclosporin,
tacrolimus) or rituximab are recommended as alternative options or for non-responders.
8.9 (1.2) 9 (2)
4.5. Azathioprine (AZA) (2 mg/kg/day) may be considered as an alternative to MPA or CY in selected patients without adverse prognostic
factors (as defined in 4.2), or when these drugs are contraindicated, not tolerated or unavailable. Azathioprine use is associated with a higher flare
risk.
8.6 (1.3) 9 (2)
Subsequent treatment
4.6. In patients improving after initial treatment, subsequent immunosuppression is recommended with either MPA at lower doses (initial
target MMF dose 2 g/day) or AZA (2 mg/kg/day) for at least 3 years, in combination with low dose prednisone (5–7.5 mg/day). Gradual drug
withdrawal, glucocorticoids first, can then be attempted.
9.4 (0.9) 10 (1)
4.7. Patients who responded to initial treatment with MPA should remain on MPA unless pregnancy is contemplated, in which case they
should switch to AZA at least 3 months prior to conception
9.4 (0.8) 10 (1)
4.8. Calcineurin inhibitors can be considered in pure class V nephritis 9.1 (1.2) 10 (2)
Refractory disease
4.9. For patients who fail treatment with MPA or CY either because of lack of effect (as defined in 3.2) or due to adverse events, we
recommend that the treatment is switched from MPA to CY, or CY to MPA, or rituximab be given
9.2 (1.0) 10 (1)
5. Adjunct treatment in patients with LN
5.1. Angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers are indicated for patients with proteinuria (UPCR >50 mg/
mmol) or hypertension
9.7 (0.8) 10 (0)
5.2. Cholesterol lowering with statins is indicated for persistent dyslipidaemia (target low-density lipoprotein (LDL)-cholesterol 2.58 mmol/litre (100 mg/dl)) 9.2 (1.3) 10 (1)
5.3. Hydroxychloroquine is recommended to improve outcomes by reducing renal flares and limiting the accrual of renal and cardiovascular
damage
9.3 (1.7) 10 (1)
5.4. Acetyl-salicylic acid in patients with anti-phospholipid antibodies, calcium and vitamin D supplementation, and immunisations with non-live
vaccines may reduce treatment or disease-related comorbidities and should be considered
9.3 (1.3) 10 (1)
5.5. Consider anticoagulant treatment in nephrotic syndrome with serum albumin <20 g/litre, especially if persistent or in the presence of
anti-phospholipid antibodies
9.2 (1.1) 10 (1)
6. Monitoring and prognosis of LN
6.1. Active LN should be regularly monitored by determining at each visit body weight, blood pressure, serum creatinine and eGFR, serum
albumin, proteinuria, urinary sediment (microscopic evaluation), serum C3 and C4, serum anti-dsDNA antibody levels and complete blood cell
count. Anti-phospholipid antibodies and lipid profile should be measured at baseline and monitored intermittently.
9.3 (0.9) 10 (1)
6.2. Changes in serum creatinine (eGFR), proteinuria, haemoglobin levels and blood pressure are predictors of long-term outcome in LN 9.2 (1.2) 10 (1)
6.3. Visits should be scheduled every 2–4 weeks for the first 2–4 months after diagnosis or flare, and then according to the response to
treatment. Monitoring for renal and extra-renal disease activity should be lifelong at least every 3–6 months.
9.1 (1.4) 10 (1)
6.4. Repeat renal biopsy may be used in selected cases, such as worsening or refractoriness to immunosuppressive or biological treatment
(failure to decrease proteinuria by ≥50%, persistent proteinuria beyond 1 year and/or worsening of GFR), or at relapse, to demonstrate change or
progression in histological class, change in biopsy chronicity and activity indices, to provide prognostic information, and detect other pathologies
9.2 (1.4) 10 (1)
Continued
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RESULTS AND DISCUSSION
Indications for ﬁrst renal biopsy in SLE
Because of the potentially aggressive nature of LN, the thresh-
olds for performing a renal biopsy should be low. Any sign of
renal involvement—in particular, reproducible proteinuria
≥0.5 g/24 h especially with glomerular haematuria and/or cellu-
lar casts—can be an indication for biopsy. Clinical, serological or
laboratory tests cannot accurately predict histological ﬁndings.
Although clinically relevant biopsy ﬁndings are more common
in the presence of signiﬁcant proteinuria, a biopsy may also be
considered in cases of persisting isolated glomerular haematuria,
isolated leucocyturia (after other causes, such as infection or
drugs are excluded),3 4 and the rare occurrence of unexplained
renal insufﬁciency with normal urinary ﬁndings. Lower glom-
erular ﬁltration rate (GFR) is associated with chronic histological
lesions and faster rate of decline in GFR.5–9 Methods for estimat-
ing GFR such as the Cockcroft–Gault and the Modiﬁcation of
Diet in Renal Disease equations in adults or the Schwartz
formula in children, although not fully validated in SLE,10 11 are
acceptable in clinical practice. For GFR <30 ml/min the decision
for biopsy should be based on normal kidney size (>9 cm length
in adults) and/or evidence of renal disease activity, in particular
proteinuria and active urinary sediment (dysmorphic red blood
cells (glomerular haematuria), white blood cells and/or cellular
casts). Biopsy should be performed within the ﬁrst month after
disease onset, preferably before the institution of immunosup-
pressive treatment, unless contraindicated.12–14 Treatment with
high-dose glucocorticoids should not be delayed if a renal biopsy
cannot be readily performed.
Pathological assessment of renal biopsy
We recommend using the International Society of Nephrology/
Renal Pathology Society 2003 classiﬁcation system15–17 with
assessment of active and chronic glomerular and tubulointersti-
tial changes,18–21 and of vascular lesions associated with anti-
phospholipid antibodies/syndrome.22 23 An adequate sample of
≥8 glomeruli should be examined under light microscopy15 24
with haematoxylin and eosin, periodic acid-Schiff, Masson’s
trichrome and silver stain. Immunoﬂuorescence or immunohis-
tochemistry for immunoglobulin and complement deposits
(IgG, IgA, IgM, C3, C1q, κ and λ light chains) is recom-
mended.12 21 25 26 Electron microscopy facilitates the recogni-
tion of proliferative and membranous lesions and should be
performed if possible.19 27–29
Indications and goals of immunosuppressive treatment in LN
Ultimate goals of treatment are long-term preservation of renal
function, prevention of ﬂares, avoidance of treatment-related
harms, and improved quality of life and survival. Treatment
must be based on a shared decision between patient and
doctor. Immunosuppressive treatment is generally not indicated
in classes I and VI LN, unless necessitated by extra-renal lupus
activity.30–32
Treatment should aim for complete renal response, deﬁned as
urine protein:creatinine ratio (UPCR) <50 mg/mmol (roughly
equivalent to proteinuria <0.5 g/24 h) and normal or near-
normal (within 10% of normal GFR if previously abnormal)
GFR. Partial renal response, deﬁned as ≥50% reduction in pro-
teinuria to subnephrotic levels and normal or near-normal GFR,
should be achieved preferably by 6 months and no later than
12 months following treatment initiation.9 33–35 Improvement
includes any reduction in proteinuria and normalisation or sta-
bilisation of GFR. Although partial response carries worse prog-
nosis than complete response,34 36 37 it may be an acceptable
outcome when all treatments have been exhausted or cannot
be used due to high individual risks for toxicity. Following
response, patients may experience nephritic or proteinuric
ﬂares, the former having more adverse impact on renal out-
comes.34 37–39 Nephritic ﬂares include reproducible increase of
serum creatinine by ≥30% (or, decrease in GFR by ≥10%) and
active urine sediment with increase in glomerular haematuria
by ≥10 red blood cells per high power ﬁeld, irrespective of
changes in proteinuria; proteinuric ﬂares include reproducible
doubling of UPCR to >100 mg/mmol after complete response
or reproducible doubling of UPCR to >200 mg/mmol after
partial response.34 37 38
Table 1 Continued
Statement
Mean
(SD)
Median
(IQR)*
7. Management of end-stage renal disease (ESRD) in LN
7.1. All methods of renal replacement treatment can be used in patients with lupus, but there may be increased risk of infections in patients on
peritoneal dialysis still on immunosuppressive agents and vascular access thrombosis in patients with anti-phospholipid antibodies
9.5 (0.8) 10 (1)
7.2. Transplantation should be performed when lupus activity has been absent, or at a low level, for at least
3– 6 months, with superior results obtained with living donor and pre-emptive transplantation. Anti-phospholipid antibodies should be sought during
transplant preparation because they are associated with an increased risk of vascular events in the transplanted kidney.
9.4 (0.9) 10 (1)
8. Anti-phospholipid syndrome-associated nephropathy in SLE
In patients with lupus and anti-phospholipid syndrome (APS)-associated nephropathy (APSN), hydroxychloroquine and/or antiplatelet/
anticoagulant treatment should be considered
9.0 (1.4) 9 (2)
9. LN and pregnancy
9.1. Pregnancy may be planned in stable patients with inactive lupus and UPCR <50 mg/mmol, for the preceding 6 months, with GFR that
should preferably be >50 ml/min. Acceptable medications include hydroxychloroquine, and where needed, low dose prednisone, azathioprine and/or
calcineurin inhibitors. The intensity of treatment should not be reduced in anticipation of pregnancy. During pregnancy, acetylsalicylic acid should be
considered to reduce the risk of pre-eclampsia. Patients should be assessed at least every 4 weeks, preferably by a specialist physician and
obstetrician.
9.3 (1.0) 10 (1)
9.2. Flare of LN during pregnancy can be treated with acceptable medications stated above depending on severity of flare 9.0 (1.5) 10 (2)
10. Management of paediatric LN
Compared to adult-onset disease, LN in children is more severe with increased damage accrual and more common at presentation but the
diagnosis, management and monitoring is similar to that of adults. A coordinated transition programme to adult specialists is important in
assessing concordance to treatments and optimising long-term outcomes.
9.6 (0.7) 10 (1)
*Numbers are mean (SD) and median (IQR) agreement level among experts. A score of 10 represents the highest level of agreement.
GFR, glomerular filtration rate; UPCR, urine protein:creatinine ratio.
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Table 2 Category of evidence and strength of statements*
Statement/item
Level of
evidence
Strength of
statement
1. Indications for first renal biopsy
Diagnostic value of urinary findings (proteinuria ≥0.5 g/24 h especially with glomerular haematuria and/or cellular casts) 2 C
Clinical, serological or laboratory tests correlate modestly with renal biopsy findings 2 B
2. Pathological assessment of kidney biopsy
International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 classification system preferred 2 C
Prognostic value of glomerular changes 1 A
Prognostic value of activity and chronicity indices 1 A
Prognostic value of tubulointerstitial lesions 2 B
Prognostic value of vascular lesions associated with anti-phospholipid antibodies 3 C
3. Indications for immunosuppressive treatment and treatment strategy
Diagnostic renal biopsy required – C
Immunosuppression for class IIIA or IIIA/C (±V) and IVA or IVA/C (±V) nephritis 1 A
Immunosuppression for class V nephritis if proteinuria >1 g/24 h 4 C
Target: preservation of renal function, prevention of disease flares, avoidance of treatment-related harms and improved quality of
life and survival
– C
Prognostic value of complete renal response (UPCR <50 mg/mmol and normal or near-normal GFR) 1 B
Prognostic value of partial renal response (≥50% reduction in proteinuria and normal or near-normal GFR) 1 B
4. Treatment of adult lupus nephritis (LN)
Class IIIA or A/C (±V) and class IVA or A/C (±V): glucocorticoids plus
Mycophenolic acid (MPA) 1 A†
Low-dose intravenous cyclophosphamide (CY) 1 B
If adverse clinical/histological prognostic factors are present: glucocorticoids plus
MPA 2 B
Low-dose intravenous CY 4 C
High-dose intravenous CY 1 A
Oral CY 3 B
Use of glucocorticoids
Three consecutive pulses of intravenous methylprednisolone 500–750 mg 3 C
Then, oral prednisolone 0.5 mg/kg/day for 4 weeks with subsequent tapering – C
Pure class V nephritis with nephrotic-range proteinuria: glucocorticoids plus
MPA 2 B
High-dose intravenous CY 2 A
Ciclosporin (increased rates of relapse of nephrotic syndrome) 2 A
Tacrolimus 3 B
Rituximab 4 C
Azathioprine (AZA) use in LN
In selected patients without adverse clinical or histological prognostic factors
Class III–IV nephritis 2 B
Class V nephritis (non-nephrotic-range proteinuria) 4 C
When MPA or CY are contraindicated, not tolerated, or unavailable – C
Associated with higher relapse risk 2 B
Subsequent immunosuppression in class III–IV or V nephritis
MPA or AZA, in combination with low-dose glucocorticoids 1 A
Successful induction with MPA followed by continuing MPA – C
AZA preferred if pregnancy planned – C
Duration of immunosuppressive treatment: at least 3 years 3 C
Gradual drug withdrawal, glucocorticoids first, can then be attempted – C
Calcineurin inhibitors can be considered in pure class V nephritis 4 C
Failure to treatment with MPA or CY
Switch from MPA to CY 4 C
Switch from CY to MPA 4 C
Add or switch to rituximab 4 C
5. Adjunct treatment
Angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for proteinuria or hypertension 2 B
Cholesterol lowering with statins for persistent dyslipidaemia – C
Hydroxychloroquine 3 C
Acetyl-salicylic acid in patients with anti-phospholipid antibodies – C
Calcium and vitamin D supplementation – C
Continued
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Table 2 Continued
Statement/item
Level of
evidence
Strength of
statement
Immunisations with non-live vaccines – C
Anticoagulant treatment in nephrotic syndrome with serum albumin <20 g/litre – C
Monitoring and prognosis of LN
Serum creatinine and GFR, proteinuria, and urinary microscopy to define activity – C
Body weight and blood pressure measurement to assess activity and response to treatment – C
Diagnostic utility of
Serum C3 2 B
Serum C4 2 B
Serum anti-dsDNA 2 B
Complete blood cell count 3 C
Serum albumin 3 C
Prognostic value of
Anti-phospholipid antibodies 2 B
Serum lipids 2 B
Prognostic value of serial changes in
Serum creatinine/GFR 1 A
Proteinuria 1 A
Haemoglobin 2 B
Blood pressure 1 A
Frequency of monitoring
Every 2–4 weeks for the first 2–4 months after diagnosis or flare – C
Lifelong at least 3–6 monthly – C
Repeat renal biopsy
Useful in worsening or refractory disease or at relapse 3 C
Strong prognostic value of renal biopsy findings 2 B
7. End-stage renal disease (ESRD) in systemic lupus erythematosus (SLE)
All methods of renal replacement treatment are safe 2 B
Increased risk for infections in patients on peritoneal dialysis 2 B
Increased risk for vascular access thrombosis with anti-phospholipid antibodies 3 C
Transplantation.
Better outcome when lupus activity is absent or at a low level for 3–6 months 3 C
Better outcome with living versus cadaveric donor 2 B
Better outcome with pre-emptive transplantation 3 C
Increased risk for vascular events in patients with anti-phospholipid antibodies 2 B
8. Treatment of anti-phospholipid syndrome (APS)-associated nephropathy (APSN)
Hydroxychloroquine – C
Antiplatelet/anticoagulation treatment – C
9. LN and pregnancy
Safe in inactive SLE with UPCR <50 mg/mmol for the preceding 6 months 2 B
GFR preferably above 50 ml/min – C
Safety and efficacy of the following medications
Hydroxychloroquine 3 B
Low-dose prednisone 4 C
Azathioprine 4 C
Calcineurin inhibitors 4 C
Intensity of treatment should not be reduced in anticipation of pregnancy – C
Acetylsalicylic acid to reduce the risk of pre-eclampsia 3 C
Assessment every 4 weeks, preferably by a specialist physician and obstetrician – C
Flare of nephritis can be treated with same acceptable medications but also with calcineurin inhibitors, intravenous
immunoglobulin, immunoadsorption and plasma exchange
– C
10. Paediatric LN
More common at presentation compared to adult-onset SLE 1 A
More severe with increased damage accrual compared to adult-onset disease 2 B
Similar monitoring with adults 3 C
Similar treatment with adults 3 C
Importance of coordinated transition programme to adult specialists – C
*Quality of evidence was graded 1–4 and the strength of statements was graded A–C (refer to web-only appendix table 1 for details).
†MPA refers to either mycophenolate mofetil (MMF) or enteric-coated MPA sodium at equivalent dose based on evidence for comparable efficacy of the two regimens. MMF
has been used in most controlled trials in LN.
dsDNA, double-stranded DNA; GFR, glomerular filtration rate; UPCR, urine protein:creatinine ratio.
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Treatment of adult LN
Initial treatment
Patients with LN should be managed, if possible, in experienced
centres.40 Early trials of immunosuppressive agents have high-
lighted the importance of long-term (beyond 5 years) follow-up
in demonstrating differences in ‘hard’ outcomes such as doub-
ling of serum creatinine, end-stage renal disease (ESRD) and
death.41–43 Such outcomes, however, are not frequent and may
occur late in the course of LN. Intermediate outcome measures,
such as renal response and ﬂares, occurring in the majority of
patients within the ﬁrst 2 years after treatment initiation, cor-
relate with hard outcomes in studies with long-term follow-up
and are commonly used as endpoints in trials.9 33–35 37–39 44
Correlation does not guarantee surrogacy of these outcomes for
all patients, some of whom may still have hard outcomes diver-
ging from their intermediate outcomes.
To date, long-term data are not available for MPA (box 1).
Nonetheless, the publication of the Aspreva Lupus
Management Study (ALMS) trial,45 the largest trial in LN
showing comparable response rates between MPA (target
mycophenolate mofetil (MMF) dose 3 g/day) and intravenous
cyclophosphamide (CY) (monthly pulses 0.5–1 g/m2), both
administered for 6 months, together with the ease of adminis-
tration and the more favourable gonadal toxicity proﬁle of the
former,46–48 formed the basis for recommending MPA as initial
treatment for most cases of class III–IV LN. Evidence from
transplantation medicine49 50 and a single randomised con-
trolled trial (RCT) in LN51 suggests that MMF and enteric-
coated mycophenolic acid sodium (eMPA) are likely to be
equally efﬁcacious. To this end, and while awaiting further val-
idation, the Committee felt that either MPA formulation can
be used in treatment of LN, with 720 mg dose eMPA roughly
equivalent to 1 g dose of MMF. We also recommend low-dose
intravenous CY (total dose 3 g over 3 months) in combination
with glucocorticoids (0.5 mg/kg/day) as initial treatment of
class III–IV (±V) LN in Caucasians based on better efﬁcacy/
toxicity ratio than high-dose intravenous CY.44 52
A single RCT in patients with pure class V LN demonstrated
that the combination of glucocorticoids with intravenous CY
(6 bimonthly pulses 0.5–1 g/m2) was more efﬁcacious than glu-
cocorticoids alone; the combination of glucocorticoids with
ciclosporin was also efﬁcacious but was associated with signiﬁ-
cantly more relapses of nephrotic syndrome than CY.53
Moreover, combined analysis of two other RCTs in the sub-
group of patients with pure class V LN showed a comparable
antiproteinuric effect of MPA versus high-dose intravenous
CY.54 By extrapolation from these studies, and based on the
more favourable gonadal toxicity proﬁle of MPA compared to
CY, we recommend MPA as initial treatment for most cases of
class V LN and nephrotic-range proteinuria. The low-dose CY
regimen has not been tested in pure class V LN.
Subgroup analysis suggests that MPA may have greater efﬁ-
cacy in patients of African descent;45 55 further conﬁrmation is
needed before issuing a recommendation favouring MPA in
these patients. Post hoc analysis in 32 patients in ALMS with
baseline GFR<30 ml/min/1.73 m2,45 and evidence from 2 con-
trolled studies in severe histological forms of LN,56 57 support
the use of MPA in patients with impaired renal function or
crescents. Only high-dose intravenous CY has demonstrated
efﬁcacy in a RCT speciﬁcally designed to include severe neph-
ritic cases with GFR 25–80 ml/min or with crescents/necrosis
in >25% of glomeruli.58 Data from a RCT59 and the 10-year
follow-up60 suggest that azathioprine can be used in class
III–IV LN albeit at an increased risk for renal relapse (HR 4.5),
thus the committee recommends it for milder cases (preserved
renal function and no adverse histological ﬁndings).
Intravenous methylprednisolone (MP) pulses are recom-
mended as part of the initial treatment regimen by extrapola-
tion from controlled studies,43 52 61 62 to decrease cumulative
glucocorticoid dose and associated harms. Higher initial gluco-
corticoid dose (oral prednisone 0.7–1 mg/kg/day) may be used
in severe renal or extra-renal lupus, or when intravenous MP
treatment is not feasible. Clinical experience suggests that a
further course of three intravenous MP pulses can be considered
in patients failing to improve within the ﬁrst 3 months.
For class II LN with proteinuria >1 g/24 h despite
renin-angiotensin-aldosterone system (RAAS) blockade, espe-
cially in the presence of glomerular haematuria, we recom-
mend low-to-moderate doses of glucocorticoids (prednisone
0.25–0.5 mg/kg/day) alone or in combination with azathiopr-
ine (1–2 mg/kg/day), if needed, as steroid-sparing agent.
Glucocorticoids alone or in combination with immunosup-
pressive agents may also be considered in cases of class I LN
with podocytopathy on the electron microscopy (minimal
change disease)63 64 or interstitial nephritis.65 66
Subsequent treatment
For patients improving after initial treatment, we recommend
subsequent immunosuppression to consolidate renal response
and prevent ﬂares. Although among patients from European
ancestries azathioprine and MPA were equivalent after initial
treatment with low-dose intravenous CY,67 a larger RCT sug-
gested a difference between the two drugs in favour of MPA
after initial response to either MPA or intravenous CY (monthly
pulses 0.5–1 g/m2).68 In this trial, sequential use of azathioprine
after MPA resulted in more treatment failures as compared to
Box 1 Research agenda
• Special training sessions for renal pathologists to improve the
interpretation of renal biopsy ﬁndings in lupus nephritis (LN)
and enhance interobserver agreement
• Development and validation of biomarkers which will better
reﬂect kidney biopsy ﬁndings and renal disease activity and
severity
• Long-term (beyond 5 years) efﬁcacy and safety data for
mycophenolic acid
• Provide data to guide duration of immunosuppressive
treatment beyond 3 years
• Deﬁne the role of adding calcineurin inhibitors, rituximab or
belimumab to standard immunosuppressive treatment in
cases with residual renal disease
• Need for more data on switching regimens in cases of
treatment failure
• Larger studies with extended follow-up are needed to assess
the prognostic signiﬁcance of anti-phospholipid syndrome
(APS)-associated nephropathy (APSN) and coexistence of
anti-phospholipid antibodies in LN
• Need for controlled trials to assess the role of antiplatelet/
anticoagulant regimes in APSN
• Need for randomised controlled trials (RCTs) in paediatric LN
and the need to have very long follow-up (beyond 10–15 years)
to fully assess the impact of the various treatment strategies
and modalities in children
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MPA followed by MPA. The committee therefore recommends
continuation of MPA if the drug was successful as initial treat-
ment. Calcineurin inhibitors can be considered in selected cases
with preserved renal function based on evidence from RCTs.69–
71 Intravenous CY, pulsed every 3 months, may be used in
selected cases43 58 72 but exposure to CY should be minimised,
especially in women at risk for amenorrhoea and infertility73 or
men planning to father children.
There is no data to guide duration of treatment beyond
3 years;67 68 continuing treatment for longer time periods
should be individualised with an effort ﬁrst to withdraw gluco-
corticoids before immunosuppressive agents. Gradual drug
dosage titration may be attempted to ensure the best possible
efﬁcacy/toxicity ratio. MPA dose often needs titration to reduce
toxicity (doses 1–2 g/day can be effective for long-term treat-
ment). Monitoring MPA blood levels to minimise harm and
increase efﬁcacy is under investigation74–76 but it should be
considered in cases with GFR <30 ml/min.
Refractory disease
Complete renal response can take up to 2 years to reach with
<30% to 40% of patients achieving this outcome within the
ﬁrst 6 months of treatment.48 59 Switching to an alternative
agent is recommended for patients who fail to improve
within 3–4 months, or do not achieve partial response after
6–12 months, or complete response after 2 years of treatment.
For patients not responding to MPA or CY, evidence from uncon-
trolled studies suggests that treatment may be switched from
MPA to CY, from CY to MPA,77 78 or that rituximab (anti-CD20
mAb) may be given either as add-on treatment or as monother-
apy.79 80 Additional options include calcineurin inhibitors
(ciclosporin A, tacrolimus),81–83 intravenous immunoglobulin,84
plasma exchange for rapidly progressive glomerulonephritis,49 85
or immunoadsorption for patients who have failed or cannot
tolerate other treatments.86 87 Data on leﬂunomide are
limited.88
Adjunctive treatment in patients with LN
We recommend control of cardiovascular disease risk factors in
a manner similar to patients who do not have SLE with
chronic kidney disease, although beneﬁt has not been demon-
strated speciﬁcally in SLE.89 Complications of chronic renal
insufﬁciency (anaemia, cardiovascular disease, metabolic bone
disease) should also be managed as in patients who do not
have SLE. RAAS blockers are recommended as preferred treat-
ment in all patients who are not pregnant with signiﬁcant pro-
teinuria or hypertension, based on: (a) evidence for their
antihypertensive, antiproteinuric and renoprotective effect,90–92
and, (b) lack of data on the comparative efﬁcacy of other
classes of antihypertensive agents in LN. Their dose is titrated
for maximum antiproteinuric effect while monitoring
blood pressure (target level <130/80 mm Hg), serum potassium
and GFR levels. Epidemiological studies93 94 and the follow-up
of a controlled trial95 demonstrate that hydroxychloroquine
use is associated with higher rates of renal response, fewer
renal relapses and reduced accrual of renal damage.
Hydroxychloroquine (6.5 mg/kg/day or 400 mg/day, whichever
is lower) is generally safe in patients with normal baseline oph-
thalmological examination; dose adjustments may be necessary
in patients with GFR <30 ml/min. Annual ophthalmological
screening begins after 5 years of treatment or sooner if there are
risk factors for retinal damage.96 Patients should also be immu-
nised with non-live vaccines according to the EULAR
recommendations.97 98
Monitoring and prognosis of LN
Patients should be monitored regularly according to EULAR
recommendations,99 including annual examination of cervicova-
ginal smear in women100 101 and measurement of serum immu-
noglobulins at baseline and then annually in patients who
receive immunosuppressive treatment to assess risk of infec-
tion. Monitoring of body weight, blood pressure, serum creatin-
ine and estimated GFR, serum albumin, proteinuria, urinary
sediment (microscopic evaluation), serum C3/C4, serum
anti-dsDNA antibody levels and complete blood cell count are
used to deﬁne activity and evaluate response to treatment
although their individual predictive value for hard outcomes at
particular time points is modest.
Spot UPCR measured on ﬁrst morning void urine sample is a
valid and conveniently repeatable measure for measuring pro-
teinuria in children and monitoring within-patient changes in
adults.102–104 Timed (12 h or 24 h) urine collections may also
be considered at baseline and when major therapeutic changes
are considered. Reappearance of urine cellular casts has >80%
sensitivity and speciﬁcity for renal ﬂares.105
Although serum C3 has generally higher sensitivity than
serum C4 (72% to 85% vs 28% to 74%), both tests have
modest speciﬁcity for active LN.106 107 The diagnostic accuracy
of serum anti-dsDNA is also modest with positive and negative
likelihood ratios ranging from 1.5–4.8 and 0.3–0.8, respectively.
Farr and ELISA methods are both acceptable, although the
former yields higher sensitivity and speciﬁcity rates.106 108–110
Anti-C1q106 111 and anti-nucleosome112–114 antibodies have
higher sensitivity and speciﬁcity for active nephritis but further
standardisation and validation are required. Changes in sero-
logical tests are more important predictors of concurrent or
impending LN ﬂare than their absolute levels but should
be repeated no more than monthly. In the absence of protein-
uria, active serology (decreasing C3/C4 and/or increasing
anti-dsDNA) and/or urine sediment is not an indication for
pre-emptive treatment but dictates closer monitoring of
patients. Repeat renal biopsy provides additional prognostic
information115–118 and can assist therapeutic decisions in
patients with relapse of nephritis after complete renal response,
or with refractory disease. It can also be used in the context of
a clinical trial to monitor treatment efﬁcacy and changes in
chronicity scores.8 119
Management of ESRD in LN
Despite immunosuppressive treatment, 10% to 30% of patients
with LN will progress to ESRD within 15 years of diagnosis.
Infections (including peritonitis) may occur in patients with
active disease still on immunosuppressive treatment, and con-
tribute to morbidity and mortality.120–123 Although clinical and
serological activity tend to subside in most patients with ESRD
on dialysis,120 124–126 ﬂares of renal or extra-renal lupus can
occur.127–130
Comparative studies131 132 and cases series133 134 support that
patients with SLE are good candidates for renal transplantation
performed when clinical (and ideally, serological) lupus activity is
absent, or at a low level, for at least 3–6 months135; best results
are obtained with living donor136–138 and pre-emptive transplant-
ation.139 Patients with moderate to high titres of anti-
phospholipid antibodies are at increased risk for thrombotic
complications and may receive anticoagulants perioperatively.140–143
Post-transplantation recurrent LN, although difﬁcult to treat, is
a rare cause of renal allograft loss.136 144 145
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Anti-phospholipid syndrome (APS)-associated nephropathy
(APSN) in SLE
Anti-phospholipid antibodies (anti-cardiolipin antibodies,
anti-β2-glycoprotein I antibodies, lupus anticoagulant) may be
associated with a distinct type of vascular nephropathy (APSN)
with adverse prognostic factors such as hypertension, impaired
renal function and interstitial ﬁbrosis.146–149 Histological
lesions of APSN are present in 20% to 30% of patients with
SLE146 150 and include thrombotic microangiopathy and
chronic lesions such as ﬁbrous intimal hyperplasia, organising
thrombi with recanalisation, focal cortical atrophy and ﬁbrous
occlusions of arteries/arterioles, thus, need to be distinguished
from thrombotic thrombocytopenic purpura/haemolytic
uraemic syndrome and malignant hypertension. In spite of lack
of evidence from controlled studies, hydroxychloroquine and/or
antiplatelet/anticoagulant treatment can be considered in com-
bination with immunosuppressive treatment if nephritis is
present. Patients with deﬁnite APS should receive anticoagula-
tion treatment.151
LN and pregnancy
Pregnancy may be planned in patients with inactive lupus and
UPCR <50 mg/mmol for the preceding 6 months, with GFR
that should preferably be >50 ml/min. Patients with LN who
are pregnant should ideally be followed by a multidisciplinary
team. Stable renal disease is treated with the same drugs
that are recommended as acceptable during prepregnancy
counselling (hydroxychloroquine, prednisone, azathioprine).
Hydroxychloroquine should be continued152 153 or even insti-
tuted if immunosuppressive agents need to be stopped. MPA or
CY should not be used in the last 3 months, and biological
agents for at least 4 months—dependent upon the agent used
before conception. Blood pressure should be controlled without
RAAS blockers at the time of conception if possible, due to
their potential teratogenic effect during the ﬁrst trimester, or
with switching to other agents such as nifedipine or labetalol
as soon as pregnancy is conﬁrmed.154 155 Acetyl-salicylic acid is
recommended to reduce the risk for pre-eclampsia.156 Patients
with APS are at increased risk for adverse pregnancy out-
comes154 157 158 and should be considered for anticoagulation
with low-molecular-weight heparin and/or acetyl-salicylic acid
depending on their history of obstetric and/or thrombotic
events.151 Warfarin must be discontinued as soon as pregnancy
is conﬁrmed. Patients with nephrotic-range proteinuria are also
candidates for anticoagulation.
For monitoring, any fall in serum C3/C4 is signiﬁcant given
than levels usually rise during pregnancy;159 additional investi-
gation may be needed to rule out pre-eclampsia before diagnos-
ing exacerbation of renal disease.160 For active disease or
pre-eclampsia, combined care with obstetricians is recom-
mended.158 Close surveillance for renal ﬂare post partum is
essential. In addition to acceptable medications used in stable
LN, refractory cases can also be treated with calcineurin inhibi-
tors, intravenous immunoglobulin, immunoadsorption and pos-
sibly plasma exchange, according to disease severity.156 161
Management of paediatric LN
Children are at increased risk for renal involvement compared
to adults with SLE (OR 1.5–2.4), and nephritis often is a
presenting feature of paediatric SLE. Together with elevated
blood pressure, fever, lymphadenopathy, skin and joint manifes-
tations,162 children with LN tend to have more active disease
over time, receive more intensive immunosuppressive treatment
and accrue more damage, often related to glucocorticoid tox-
icity, compared to adults.163–168 The diagnosis, management
and monitoring is based on extrapolation from evidence in
adults, and on the limited, non-randomised, evidence in chil-
dren with LN.169–172 Additional considerations include the
negative effect of disease activity and glucocorticoids on linear
growth, and the modiﬁcation of body image induced by treat-
ment. This may represent major psychological burden espe-
cially in adolescents building their self-esteem and affecting
treatment compliance.
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